LifeStance Health Group, Inc. LFST R2KR3KPHARMA
Company Overview
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Why Investors Should Care
Net profit has compounded at 11.3% per year over the last five years.
Revenue has grown at a 46.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.31.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.42B (+13.9% YoY); net profit $9.66M.
- Trailing 12 Months Year-on-year growth — revenue +26.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 46.3%, profit CAGR 11.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 46.30% |
| 1 Year: | 26.10% |
Compounded Profit Growth
| 5 Years: | 11.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +146.23% |
| 6 Months: | +83.69% |
| 3 Months: | +71.79% |
| 1 Month: | +19.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.26 · Neutral
P/E of 97.92 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 46.3% over 5 years.
- Profit CAGR of 11.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 97.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFST LifeStance Health Group, Inc. R2KR3KPHARMA | 12.73 | 97.92 | $4.86B | 0.00% | 1.24% | 3.43% | 46.30% | 11.26% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00K | 44.00K | - | 1.36M | - | - | - | - | - | - | - | - | - | - | 332.97M | 345.31M | 363.81M | 382.19M | 403.48M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 223.18M | 236.88M | 247.23M | 255.90M | 267.54M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 109.79M | 108.43M | 116.58M | 126.30M | 135.93M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 108.19M | 111.38M | 109.17M | 108.21M | 113.65M | - |
| Operating Income | 104.00K | 2.69M | -881.00K | -47.05M | -124.67M | -64.85M | -60.47M | -38.84M | -34.09M | -48.41M | -74.36M | -16.77M | -15.95M | 47.00K | 1.60M | -2.95M | 7.41M | 18.08M | 22.28M | 30.65M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.36M | 10.96M | 20.94M | 31.51M | 34.87M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.07M | 2.90M | 2.81M | 2.88M | 1.79M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.47M | -5.94M | 4.57M | 15.20M | 19.76M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.18M | -2.15M | 3.50M | 3.54M | 5.52M | - |
| Net Income | -4.34M | -3.29M | -8.68M | -70.03M | -120.45M | -62.33M | -68.73M | -37.85M | -34.24M | -45.48M | -61.58M | -21.10M | -23.28M | 709.00K | 709.00K | -3.79M | 1.08M | 11.67M | 14.24M | 23.61M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | -0.01 | 0.00 | - | 0.04 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 212.52M | 1.45M | 859.54M | 1.06B | 1.25B | 1.42B |
| Operating Income | 15.24M | -286.35M | -210.17M | -189.13M | -31.61M | 24.15M |
| Net Income | 5.67M | -307.20M | -215.56M | -186.26M | -57.44M | 9.66M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Apr 2020 | May 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 1.57B | - | 2.17B | 2.11B | 2.12B | 2.20B |
| Current Assets | - | - | - | - | - | - | 233.22M | 225.73M | 312.51M | 416.20M |
| Cash & Equivalents | - | - | - | - | 18.83M | - | 108.62M | 78.82M | 154.57M | 248.64M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 100.87M | 125.41M | 131.80M | 95.71M |
| Total Liabilities | - | - | - | - | 536.89M | - | 655.15M | 681.04M | 672.01M | 682.92M |
| Current Liabilities | - | - | - | - | 75.92M | - | 176.00M | 202.87M | 228.89M | 251.96M |
| Long Term Debt | - | - | - | - | 362.53M | - | 225.08M | 280.29M | 279.79M | 265.93M |
| Total Debt | - | - | - | - | - | - | 476.49M | 511.04M | 485.19M | 474.52M |
| Total Equity | -109.10M | -166.35M | 0 | -464.38M | 997.84M | - | 1.52B | 1.43B | 1.45B | 1.52B |
| Shares Outstanding | - | - | - | - | - | - | 375.96M | 378.73M | 382.74M | 388.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 17.05M | 9.42M | 52.79M | -16.88M | 107.26M | 146.15M |
| Investing Cash Flow | -73.38M | -194.08M | -139.46M | -60.34M | -21.57M | -36.12M |
| Financing Cash Flow | 48.46M | 313.86M | 47.26M | 47.43M | -9.95M | -15.96M |
| Capital Expenditure | -14.31M | -94.49M | -79.25M | -40.52M | -21.57M | -36.12M |
| Free Cash Flow | 2.73M | -85.07M | -26.47M | -57.40M | 85.69M | 110.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 7.2% | -19,816.8% | -24.5% | -17.9% | -2.5% | 1.7% |
| Net Margin % | 2.7% | -21,259.3% | -25.1% | -17.6% | -4.6% | 0.7% |
| ROE % | -3.4% | - | -14.2% | -13.0% | -4.0% | 0.6% |
| ROCE % | - | - | -10.5% | -9.9% | -1.7% | 1.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TPG GP A, LLC | 28.81% | 111.74M | $1.38B |
| 2 | FMR, LLC | 15.02% | 58.25M | $717.09M |
| 3 | Blackrock Inc. | 9.37% | 36.35M | $447.45M |
| 4 | Summit Partners, L.P. | 6.01% | 23.31M | $286.95M |
| 5 | Vanguard Portfolio Management LLC | 3.60% | 13.96M | $171.86M |
| 6 | Jennison Associates LLC | 3.11% | 12.08M | $148.67M |
| 7 | Dimensional Fund Advisors LP | 2.95% | 11.43M | $140.67M |
| 8 | Vanguard Capital Management LLC | 2.51% | 9.74M | $119.84M |
| 9 | State Street Corporation | 2.12% | 8.23M | $101.29M |
| 10 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.53% | 5.95M | $73.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFST
LifeStance Health Group (LFST) Stock May Be Above Fair Value On Its 137% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNSHdfN05vTVByckhLc01sSkpIQm1mVHJXOFBDSm5oc1plZFluRHRzYW9vVkdyVDZKRVZGSnBkclVGdDlBUGNUbjE2ZUt1NFowWVo2bGM5ZkFJbjB2eHcyTmZyMlVhZWpCS0o3MC1yUkQ2c1NfdGdmNzdlQVB4MHNfNlYyT05WSjNTVF9jbl…
LifeStance Health Group (LFST) Following Mental Health Growth Narrative Still Looks Near Fair Value - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOajFGY0ozd1FSN01SOGpBUFRyMUN6XzlkOUdob0N0bnVIejhoUnpHY245OUJLdHVUcUFYdi1mdHJ4bU1xdGJkYnN0YUV3dnlFQlROdmhudEJLdVU3Y2JHWGFWZmVFaEg2YmRmbElwY1hnRWozQnk2OVZEZjlRLW05X1ZaRGptVGJ4LVFNeV…
CTO stock sale leaves LifeStance (LFST) insider with 205,379 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNXzFpb3ROdmd6alpTV2daM19vS05PMWd2Y1hqZVZ0WERmZTZEcm5NWTVQRmdVdGJlS0RzRm45T1pHQldyRDU1NGJFUUp1bkRhVzhpSV9lTmtyT0pCRDA4a2lYX1R6MHhUdUphamx6MS11R29kamxKVHNJTGxodlZPYmZzcGJ4d1pFeVNRRz…
LifeStance Health Group (LFST) Has Rallied Sharply, Is The Stock Still Undervalued? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQR01oZDdoaFg3LWxhNThTcDE1WjlFd0x2MW1CSjlubTB3Z05RRFhvLWk4ZG5OV09HV1NHcW1fLXlCR3I3YWFXNUxFRGlvZm1SZnVDWG1PYVIxb1JLdVFHeHNENEhQcWZhRGRGSExBNVp2LUZlVUVfQk1VZGt4UmctRWRDZm1PY3AyZWI4MD…
Trading the Move, Not the Narrative: (LFST) Edition - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNQnBwdS1QdS1FNXZlVXlSdE1GeHhvVzQ2RG5kTGFfRUp0M01CeEQ4TFhoZWlBWmxOdjFiYnhtekZpOWFSbUdmZFVTejNONzlhMG9mSjdqWU9ObXNyWWs5bkhDZnFFY0xvandhTzNCVlR3QUVmcXo5Z0ZKUERWSy1iQ2xnaW5rU1VlZEcxU2…
LifeStance Health Stock 9-Day Winning Spree: Stock Climbs 33% - Trefis
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPX2x4cHI3c2xldjBKUzJJRzgxd0gyQnQwbzZHUExmTXlrZWdOR0VWX2JtOGc5cGs4MkNhRlJFVk15bTQ2VFQ1Tms2WFFPdE5LOGhxOVpqQmoxdGpuck5PVEN6d1pMRm84Y0tnMVJNaC0zSm1JcVVTZWNqbEFaMzZMRWlxVWk0LVdQdFRWWU…
LFST — Frequently Asked Questions
What is the current share price of LifeStance Health Group, Inc. (LFST)?
As of 2026-09-07 16:24 PDT, LifeStance Health Group, Inc. (LFST) trades at $12.73 on NasdaqGS. Its 52-week range is $4.81 to $12.89.
What is the market capitalisation of LFST?
LifeStance Health Group, Inc. (LFST) has a market capitalisation of $4.86B on NasdaqGS.
What is the P/E ratio of LFST?
LFST trades at a trailing price-to-earnings (P/E) ratio of 97.92. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.80.
What is the return on equity (ROE) of LFST?
LFST has a return on equity (ROE) of 3.43%. Its return on capital employed (ROCE) is 1.24%.
Is LFST a good stock to buy?
This page provides a data-driven analysis of LifeStance Health Group, Inc. (LFST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.